Sanofi SNY
Sanofi (Nasdaq: SNY) is an immunology/inflammation drug developer. Its lead program, Dupixent (dupilumab; marketed portfolio), is in Phase 3 for Atopic dermatitis and other type 2 inflammatory diseases. Its next catalyst on record is rilzabrutinib (Wayrilz): Start of Phase 3 in asthma (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: rilzabrutinib (Wayrilz) — Start of Phase 3 in asthma (2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Dupixent (dupilumab) | Atopic dermatitis, asthma, COPD, CSU, bullous pemphigoid, others | antibody | Approved |
| Qfitlia (fitusiran) | Hemophilia A or B | RNA (siRNA/ASO/mRNA) | Approved |
| Wayrilz (rilzabrutinib) | Immune thrombocytopenia | small molecule | Approved |
| tolebrutinib | Secondary progressive multiple sclerosis | small molecule | Phase 3 |
| amlitelimab | Atopic dermatitis | antibody | Phase 3 |
| duvakitug | Ulcerative colitis; Crohn's disease | antibody | Phase 3 |
| itepekimab | COPD; chronic rhinosinusitis with nasal polyps | antibody | Phase 3 |
| lunsekimig | COPD (Phase 3); asthma (Phase 2) | antibody | Phase 3 |
| frexalimab | Relapsing MS; non-relapsing secondary progressive MS | antibody | Phase 3 |
| riliprubart | CIDP | antibody | Phase 3 |
| venglustat | Fabry disease; Gaucher disease type 3 | small molecule | Phase 3 |
| elenestinib | Indolent/smoldering systemic mastocytosis | small molecule | Phase 3 |
Recent results and decisions
- Oct 1, 2026n/a Sanofi and Regeneron expand alliance to co-develop four next-generation long-acting immunology antibodies with $1 billion upfront and up to $7 billion in milestones.
Regeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits
Filing - Oct 1, 2026started REGN20423, a long-acting IL-13 monoclonal antibody, is currently in a Phase 1 clinical study for atopic dermatitis.
IL-13 antibody REGN20423 is currently in a phase 1 clinical study for atopic dermatitis
Filing - Aug 4, 2026approval European Commission approved extension of MenQuadfi to infants from six weeks of age, based on MET58 immunogenicity data (ex-US regulatory action).
Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age to help protect against invasive meningococcal disease caused by Neisseria meningitidis se
Filing
68 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.